#Japan #Tokyo #Oops WOMB #Asuka Pharmaceutical #Slinda Tablet

Enhancing Patient Care: The Collaboration Between Oops WOMB and Asuka Pharmaceutical

In recent developments within the healthcare sector, Oops WOMB, an online prescription service managed by SQUIZ, and Asuka Pharmaceutical have initiated a collaboration aimed at improving the distribution of domestic approved medications and increasing understanding of patient needs. This partnership is fundamental in raising awareness about women’s health issues while providing a platform for educational seminars.

Introduction to Oops WOMB

Oops WOMB was launched in April 2021, presenting a range of online diagnostic services tailored to suit various healthcare needs. Its portfolio includes services for erectile dysfunction (Oops LOVE), hair loss (Oops HAIR), contraceptive prescribing (Oops WOMB), and mental care (Oops HEART). The service is designed to create a more approachable atmosphere for individuals facing sensitive health concerns. Moreover, Oops WOMB aims to change the negative perceptions surrounding complex health issues by promoting education and information dissemination.

Purpose of the Recent Seminar

The seminar conducted by Oops WOMB concentrated on the needs for online prescriptions and highlighted the communication gaps regarding contraceptive options available in Japan, particularly focusing on the newly approved Slinda Tablet 28 from Asuka Pharmaceutical. The meeting served as the first step in their information-sharing process, promoting literacy surrounding women’s health and the significance of appropriate medication usage within the community.

Key Highlights from the Seminar

The seminar agenda included:

• - Overview of the online consultation process
• - Patient needs assessment for contraceptive options, with a focus on Slinda Tablet 28
• - Presentation of pre-survey results regarding the acceptance of domestic approved medications
• - Q&A session for interactive feedback

The speakers addressed crucial psychological barriers associated with access to pharmaceuticals, discussing misconceptions surrounding contraception and how Oops WOMB has successfully navigated these hurdles. Furthermore, they presented specific case studies demonstrating how employing online consultations combined with effective design and communication strategies led to successful patient engagement.

Surveys and Findings

Ahead of the Slinda Tablet's launch, Oops WOMB conducted a pre-survey in May 2025 to assess public awareness of mini-pills and the preference for domestic options. The survey revealed surprising insights: a staggering 92% of respondents were unaware that the so-called mini-pills available in Japan were unapproved foreign products. Furthermore, 80% expressed a willingness to choose a domestic approved medication, even if it cost 1.8 times more than unapproved alternatives.

These findings stress the urgent need for effective communication strategies to enhance public understanding and promote the benefits of approved medications, paving the way for additional collaborations across different sectors to advance medical knowledge and care.

Feedback from Participants

Feedback collected from participating Medical Representatives post-seminar emphasized the importance of understanding patients' backgrounds and perspectives, and several noted the seminar was a compelling reminder of the transformative potential of online consultations. Participants were particularly resonant with the idea of shifting the narrative surrounding pills from negative to positive, fostering thought-provoking discussions on the role of pharmaceutical companies in addressing these concerns.

Conclusion

The ongoing collaboration between Oops WOMB and Asuka Pharmaceutical illustrates a proactive approach to refining the healthcare experience for patients. With online consultations allowing for the accumulation and analysis of comprehensive data, there exist tremendous opportunities to enhance patient understanding and expand access to vital healthcare knowledge.

As they move forward, Oops WOMB will continue to collaborate with pharmaceutical companies and other sectors to ensure that accurate information and effective care reach the public, epitomizing the commitment to improving healthcare access and literacy across social platforms.

Company Overview

Company Name: SQUIZ Co., Ltd.
CEO: Tomoaki Hirano
Headquarters: 7th Floor, Yamaha Building, 2-16-7 Yoyogi, Shibuya-ku, Tokyo
Service URL: Oops WOMB Official Site

For media inquiries, please contact:
SQUIZ Public Relations Department
Tel: 03-4405-3013
Email: [email protected]